Includes Current Assets, Liabilities and Stockholder's Equity
Fiscal Year Ended Dec 31, 2020
As of December 31, 2020, Adaptimmune had cash and cash equivalents of $56.9 million and Total Liquidity of $368.2 million.
Revenue for the fourth quarter and year ended December 31, 2020 was $1.5 million and $4.0 million.
For Fiscal Year Ending Dec 31, 2020
For complete information regarding our financials, see our periodic filings